Interest of the addition of taxanes to standard treatment in first-line advanced her2 positive gastroesophageal adenocarcinoma in selective patients

HIGHLIGHTS

• who: Emeline Orillard from the Nanjing Drum Tower Hospital, China University of Texas MD Anderson have published the paper: Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients, in the Journal: (JOURNAL)
• what: The Despite the small number of patients, median PFS and OS in the S group remain comparable to the ToGA study, with 5.6 and 12.9 months, respectively in the study compared to 6.7 and 13.8 months in the ToGA study . The study has several limits naturally related . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.